Long-term relative survival after diagnosis of testicular germ cell tumor

Cancer Epidemiology Biomarkers and Prevention

Volumn 25, Issue 5, 2016, Pages 773-779

  Kvammen, Øivind ^a   Myklebust, Tor Å ^b   Solberg, Arne ^a   Møller, Bjørn ^b   Klepp, Olbjørn H ^c   Fosså, Sophie D ^d   Tandstad, Torgrim ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b CANCER REGISTRY OF NORWAY   (Norway)

^c Alesund Hospital   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; MITHRAMYCIN; VINCRISTINE;

ADJUVANT RADIOTHERAPY; ADOLESCENT; ADULT; AGE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LONG TERM SURVIVAL; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; NORWAY; OVERALL SURVIVAL; PRIORITY JOURNAL; SEMINOMA; TESTICULAR GERM CELL TUMOR; TESTIS CANCER; COHORT ANALYSIS; MORTALITY; NEOPLASM; RISK FACTOR; SURVIVAL ANALYSIS; TESTIS TUMOR;

ADULT; COHORT STUDIES; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; RISK FACTORS; SURVIVAL ANALYSIS; TESTICULAR NEOPLASMS;

EID: 84965179599     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-15-1153     Document Type: Article

References (30)

1. Haugnes HS, Oldenburg J, Bremnes RM. Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors. Urol Oncol 2015;33: 399-406.
2. Haugnes HS, Bosl GJ, Boer H, Gietema JA, Brydøy M, Oldenburg J, et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol 2012;30:3752-63.
3. Fung C, Fossa SD, Beard CJ, Travis LB. Second malignant neoplasms in testicular cancer survivors. J Natl Compr Canc Netw 2012;10:545-56.
4. Horwich A, Fossa SD, Huddart R, Dearnaley DP, Stenning S, Aresu M, et al. Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer 2014;110:256-63.
5. Ondrus D, Ondrusova M, Friedova L. Second malignancies in long-term testicular cancer survivors. Int Urol Nephrol 2013;46:749-56.
6. Fung C, Fossa SD, Milano MT, Oldenburg J, Travis LB. Solid tumors after chemotherapy or surgery for testicular nonseminoma: A population-based study. J Clin Oncol 2013;31:3807-14.
7. Kero AE, Jarvela LS, ArolaM,Malila N, Madanat-Harjuoja LM, Matomaki J, et al. Cardiovascular morbidity in long-term survivors of early-onset cancer: A population-based study. Int J Cancer 2014;134:664-73.
8. Hauptmann M, Fossa SD, Stovall M, van Leeuwen FE, Johannesen TB, Rajaraman P, et al. Increased stomach cancer risk following radiotherapy for testicular cancer. Br J Cancer 2015;112:44-51.
9. Beard CJ, Travis LB, Chen MH, Arvold ND, Nguyen PL, Martin NE, et al. Outcomes in stage I testicular seminoma: A population based study of 9193 patients. Cancer 2013;119:2771-7.
10. Gandaglia G, Becker A, Trinh QD, Abdollah F, Schiffmann J, Roghmann F, et al. Long-term survival in patients with germ cell testicular cancer: A population-based competing-risks regression analysis. Eur J Surg Oncol 2014;40:103-12.
11. Skyrud KD, Bray F, Møller B. A comparison of relative and cause-specific survival by cancer site, age and time since diagnosis. Int J Cancer 2014;135:196-203.
12. Perme MP, Stare J, Est-eve J. On estimation in relative survival. Biometrics 2012;68:113-20.
13. Larsen IK, Sma- stuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, et al. Data quality at the Cancer Registry of Norway: An overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009;45:1218-31.
14. Klepp O, Klepp R, Host H, Asbjornsen G, Talle K, Stenwig AE. Combination chemotherapy of germ cell tumors of the testis with vincristine, adriamycin, cyclophosphamide, actinomycin D and medroxyprogesterone acetate. Cancer 1977;40:638-46.
15. Klepp O, Olsson AM, Henrikson H, Aass N, Dahl O, Stenwig AE, et al. Prognostic factors in clinical stage I nonsemitomatous germ cell tumors of the testis: Multivariate analysis of a prospective multicenter study. Swedish-Norwegian Testicular Cancer Group. J Clin Oncol 1990;8:509-18.
16. Tandstad T, Dahl O, Cohn-Cedermark G, Cavallin-Stahl E, Stierner U, Solberg A, et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: The SWENOTECA management program. J Clin Oncol 2009;27:2122-8.
17. Tandstad T, Smaaland R, Solberg A, Bremnes RM, Langberg CW, Laurell A, et al. Management of seminomatous testicular cancer: A binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol 2011;29:719-25.
18. Cohn-Cedermark G, Stahl O, Tandstad T; SWENOTECA. Surveillance vs. adjuvant therapy of clinical stage I testicular tumors-a review and the SWENOTECA experience. Andrology 2015;3:102-10.
19. Brown CC. The statistical comparison of relative survival rates. Biometrics 1983;39:941-8.
20. Spermon JR,Witjes JA, Kiemeney LA. Difference in stage and morphologyadjusted survival between young and elderly patients with a testicular germ cell tumor. Urology 2002;60:889-93.
21. Thomsen FB, Bandak M, Thomsen MF, Lauritsen J, Christensen IJ, Daugaard G. Survival and toxicity in patients with disseminated germ cell cancer aged 40 years and older. Cancer 2014;120:43-51.
22. Fossa- SD, Cvancarova M, Chen L, Allan AL, Oldenburg J, Peterson DR, et al. Adverse prognostic factors for testicular cancer-specific survival: A population-based study of 27,948 patients. J Clin Oncol 2011;29: 963-70.
23. Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: A period analysis. Lancet 2002;360:1131-5.
24. Robinson D, Møller H, Horwich A. Mortality and incidence of second cancers following treatment for testicular cancer. Br J Cancer 2007; 96:529-33.
25. Fossa- SD, Chen J, Schonfeld SJ,McGlynn KA, McMaster ML,Gail MH, et al. Risk of contralateral testicular cancer: A population-based study of 29,515 U.S. men. J Natl Cancer Inst 2005;97:1056-66.
26. Zagars GK, Ballo MT, Lee AK, Strom SS. Mortality after cure of testicular seminoma. J Clin Oncol 2004;22:640-7.
27. Hallemeier CL, Choo R, Davis BJ, Leibovich BC, Costello BA, Pisanky TM. Excellent long-term disease control with modern radiotherapy techniques for stage I testicular seminoma-the Mayo Clinic experience. Urol Oncol 2014;32:24.e1-6.
28. Sun M, Abdollah F, Liberman D, Abdo A, Thuret R, Tian Z, et al. Racial disparities and socioeconomic status in men diagnosed with testicular germ cell tumors: A survival analysis. Cancer 2011;117: 4277-85.
29. Haugnes HS, Solhaug-Stenberg J, Hjelle LV, Bremnes RM. Seminoma patients treated at a minor oncological department during 1986-2010: Treatment and outcome. Anticancer Res 2014;34:4253-60.
30. Capocaccia R, Gaita G, Dal Maso L. Life expectancy of colon, breast and testicular cancer patients. An analysis of US-SEER population-based data. Ann Oncol 2015;26:1263-8.